CAR-T therapies by BMS and Janssen reported successful

CAR-T therapies that are being developed by Bristol Myers Squibb and Janssen have all hit targets in early-mid-stage trials. Increasing hopes of new treatment options for difficult to treat blood cancers. Johnson & Johnson’s Janssen unveiled initial results from the Phase Ib/II CARTITUDE-1 study assessing the efficacy and safety of JNJ-68284528 (JNJ-4528) – an investigational B cell

Continue Reading

The saddest aspect of life right now is that science gathers knowledge faster than society gathers wisdom.

Our latest CPIA report features analysis on the Biotechnology sector. Clinical Professionals Group CEO, Yvette Cleland comments: “The UK biotech businesses focused within research and experimental development have risen by 65% since 2016 and the Golden Triangle of London/Oxford and Cambridge accounts for 35% of this concentration of companies. Annual investment reached 2.2 billion in

Continue Reading

New positive results from GSK’s TB vaccine in HIV negative patients

GSK announce promising results from a study conducted in partnership with non-profit scientific research organisation IAVI, that is investigating the efficacy of the company’s tuberculosis (TB) vaccine in HIV-negative adults with latent TB infection. The study was conducted across 11 sites throughout Kenya, South Africa and Zambia, which are all TB-endemic regions, and enrolled over

Continue Reading

New clinical trial to investigate affects of CBD on Parkinson’s related psychosis

A pioneering clinical trial is set to investigate the use of cannabidiol (CBD) in people with Parkinson’s-related psychosis. Parkinson’s UK will be partnering with scientists at King’s College London in the first large-scale trial which aims to provide preliminary evidence for the safety and efficacy of CBD to alleviate the symptoms of Parkinson’s-related psychosis, characterised by hallucinations and delusions.

Continue Reading

Novartis treatment achieves positive results in possible new indication

Novartis announced positive results from its Cosentyx focused PREVENT trial, advancing the drug in potential new indication for patients with axial spondyloarthritis. The phase III study met its 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA), showing a considerable and clinically meaningful reduction in disease activity. Novartis has also submitted

Continue Reading